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Abstract:
The metabolites of N-[(tdmethylamineboryl)-carbonyl]-L-phenylalanine methyl ester 1
proved to be active in a number of pharmacological screens where the parent had previously
demonstrated potent activity. The proposed metabolites demonstrated significant activity as
cytotoxic, hypolipidemic, and anti-inflammatory agents. In cytotoxicity screens several of the
proposed metabolites afforded better activity than the parent compound against the growth of
suspended and solid tumor cell lines. Evaluation of in vivo hypolipidemic activity demonstrated
that the proposed metabolites of 1 were only moderately active and were generally less effective
than the parent compound. Interestingly, L-phenylalanine methyl ester hydrochloride 3, which
contains no boron atom, demonstrated equivalent hypolipidemic activity as the parent at 8
mg/kg/day in CF male mice. As anti-inflammatory agents the proposed metabolites
demonstrated variable capacities to reduce foot pad inflammation. These compounds were
similarly effective as the parent 1 at blocking local pain and were generally better than the parent
at protecting CF male mice from LPS induced sepsis.
Introduction"
N-[(Trimethylamineboryl)-carbonyl]-L-phenylalanine methyl ester 1 has been shown to
possess antitumor, hypolipidemic, and antiinflammatory activities in vivo [1]. Disposition and
distribution studies of this compound in CF male mice after intraperitoneal or intravenous
administration indicated it was rapidly metabolized to N-[(trimethylamineboryl)-carbonyl]-L-
phenylalanine in the plasma. In simulated gastric fluid, compound 1 was rapidly hydrolyzed to L-
phenylalanine methyl ester 3 [2]. In order to address concerns that metabolites may be
responsible for the pharmacological activity, synthesis and pharmacological evaluation of possible
metabolic products of compound 1 were undertaken. The metabolic products evaluated included
sodium N-[(trimethylamineboryl)-carbonyl]-L-phenylalanine 2, L-phenylalanine methyl ester 3, L-
phenylalanine 4, and boric acid 5. Additionally, a non-boronated derivative, N,N-dimethylglycyI-L-
phenylalanine methyl ester 6, was evaluated to determine the necessity of the boron atom for
pharmacological activity (Figure I).
Materials and Methods:
Chemistry:
Reagents and Apparatus:
All chemicals were used as received from the manufacturer. Solvents were distilled prior to
use. Trimethylamine carboxyborane was provided by Boron Biologicals, Inc. (Raleigh, NC).
All other chemicals used in the synthetic procedures were purchased from Alddch Chemical
Company (Milwaukee, Wl). A Perkin Elmer 1320 Infrared Spectrophotometer was used for
infrared (IR) analyses using KBr disks or nujol mulls between sodium chloride plates. A Varian
300 MHz NMR spectrometer was used to generate H-NMR spectra. Chemical shifts are relative
to the external standard tetramethylsilane (5 = 0). A Thomas-Hoover capillary melting point
apparatus was used to determine melting points, which were uncorrected. Elemental analyses
were performed by M-H-W Laboratories (Phoenix, AZ). Silica gel 60F 254 plates (silica gel on
aluminum, Aldrich Chemical Company) were used for thin layer chromatography.
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Figure I: Molecular Structures of the Derivatives of the Boronated Dipeptide N-
[(Trimethylamineboryl)-carbonyl]-L-phenylalanine Methyl Ester.
Synthesis:
The synthesis of boronated dipeptides was accomplished by using the coupling agent
triphenylphosphine/carbon tetrachloride (Scheme I). The conditions under which this reaction was
conducted were mild enough so that the yields were of acceptable levels compared to traditional
condensation conditions, such as thionyl chloride, that result in the formation of chloroborane
instead of the desired product [3]. The mechanism of PPh3/CCI4 condensation proceeds through
the formation of a triphenyltrichloro-methylphosphonium chloride salt and subsequent formation of
an acyloxyphosphonium salt. In the presence of an amino acid ester, the nitrogen reacts
exclusively at the carbonyl carbon of the acyloxyphosphonium salt to form the dipeptide analog
[3].
Synthetic Methods:
L-Phenylalanine methyl ester hydrochloride 3, L-phenylalanine 4, and boric acid 5, were
purchased from Aldrich Chemical Company (Milwaukee, WI). Compound 1 was synthesized by
the method of Sood et al. [1]. Compounds 2 and 6 were synthesized as follows:
Synthesis of sodium N-[(trimethy!amineborvl)-carbon1]-L-phen1alanine ()"
N-[(Trimethylamineboryl)-carbonyl]-L-phenylalanine methyl ester 1 (1 g, 3.59 mmol) was
suspended in 50 ml distilled water to which 3.6 ml of an 0.986 M aqueous sodium hydroxide
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Scheme I: The Synthesis of Derivatives of the
[(Trimethylamineboryl)-carbonyl]-L-phenylalanine Methyl Ester.
Boronated Dipeptide N-
solution (0.14 g, 3.59 mmol) was slowly added while stirring. After 15 minutes, the reaction
appeared to be complete by TLC analysis although small amounts of an insoluble white solid are
present. The white solid was removed by vacuum filtration and solvent was removed under
reduced pressure leaving a white hygroscopic solid. The white hygroscopic solid was further
purified by silica gel column chromatography using one void volume of ethyl acetate, followed by
ethyl acetate / acetonitrile (1:1) until completed. Combined pure fractions yielded 486.8 mg (47%)
of a white hygroscopic solid; Rr=0.12 in 1:1 ethyl acetate/acetonitrile. H-NMR (DMSO-d6)" 7.16
(m,5H,CH); 6.57 .(d,IH,NH); 4.35 (q,IH,CH); 3.00 (ddd,2H,CH2); 2.60 (s,9H,NMe3); 1.72
(m,2H,BH2); IR (cm)Nujo= 3450 VNH, 2380 VBH, 1575 VCONH; m.p. 95-97C (dec.). (Calcd.: C,
54.57%; H, 7.05%; N, 9.79%. Found: C, 54.33%; H, 6.95%; N, 9.57%).
Synthesis of N,N-dimethylglvcvI-L-phenylalanine methyl ester (.):
L-Phenylalanine methyl ester hydrochloride (2.09 g, 9.7 mmol) and dimethylglycine were
suspended in 30 ml dry tetrahydrofuran (THF) with triethylamine (1.4 ml, 1.01 g, 10 mmol),
dicyclohexylcarbodiimide (DCC, 2.24 ml, 2.06 g, 10 mmol) and hydroxybenzotriazole (HOBt, 1.35
g, 10 mmol). The reaction mixture was stirred at room temperature for 48 hours under nitrogen
and the solvent was removed by rotary evaporation. The product was purified by silica gel column
chromatography using two void volumes of hexane, two void volumes of hexane/ethanol (8:1),
and then hexane:ethanol (5:1). The combined fractions of purified product yielded 421.9 mg
(17%) of a clear liquid; Rr=0.35 in hexane:ethanol (1:1). H-NMR (CDCI3): (5 7.55 (d,IH,NH);
7.26 (m,5H,C6H5); ,5 4.91 (m,IH,CH); 3.73 (s,3H,OCH3); 3.18 (ddd,2H,CH2); 5 2.92 (d,2H,CH2);
2.20 (s,6H,CH3). (Calcd.: C, 63.61%; H, 7.63%; N, 10.60%. Found: C, 63.82%; H, 7.60%; N,
10.57%).
Pharmacological Assays
Compounds 1-6 were tested for cytotoxic activity by homogenizing drugs in a 1 mg/ml
solution in 0.05% Tween 80/H20. These solutions were sterilized by passing them through an
acrodisc (45 p). The following cell lines were maintained by literature techniques [4]: murine L12o
lymphoid leukemia, rat UMR 106 osteosarcoma, human Tmolt3 acute lymphoblastic T cell
leukemia, HeLa-S
3 suspended cervical carcinoma, HeLa solid cervical carcinoma, KB epidermoid
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nasopharynx, colorectal adenocarcinoma SW480, HCT-8 ileocecal adenocarcinoma, lung
bronchogenic MB-9812, A549 lung carcinoma, A431 epidermoid carcinoma, and glioma HS683.
Geran et a/.’s protocol [5] was used to assess the cytotoxicity of the compounds and standards in
each cell line. Cell numbers were determined by the trypan blue exclusion technique. Solid tumor
cytotoxicity was determined by Liebovitz et al.’s method [4] utilizing crystal violet/MeOH and read
at 562 nm (Molecular Devices). Values for cytotoxicity were expressed as EDo = pg/ml, i.e. the
concentration of the compound inhibiting 50% of cell growth. A value of less than 4 pg/ml was
required for significant activity of growth inhibition.
Antihyperlipidemic activity:
Serum cholesterol levels:
CF male mice (~28 g) were administered drugs, suspended in 1% carboxymethylcellulose
(CMC) at 8 mg/kg/day, I.P., for 16 days. On days 9 and 16, the mice were bled by tail vein
bleeding into capillary tubes. Serum was obtained by centrifugation at 3000 x g for 2 min. Total
serum cholesterol was determined by the Liebermann-Burchard reaction [6]. Lovastatin (8
mg/kg/day) and clofibrate (150 mg/kg/day) were also tested as standard cholesterol reducing
agents.
Serum triglyceride levels:
Serum triglyceride levels were determined by using a commercial kit (triglycerides GPO
Trinder 20, Sigma). Lovastatin (8 mg/kg/day) and clofibrate (150 mg/kg/day) were also included
as standard triglyceride reducing agents.
Anti-inflammatory activity:
Winter’s test:
CF male mice (~28 g) were administered experimental drugs, in 0.05% Tween 80 / water,
at 8 mg/kg doses, I.P., 3 hours and again at 30 min. prior to injection of 0.05 ml 1% carrageenin,
in 0.9% saline, into the plantar surface of the right hind foot. Saline injected into the left hind foot
served as a base line control. After 3 hours, both feet were excised at the tibiotarsal (ankle) joints
and were weighed according to the modified method of Winter [7]. The control value was 84 mg
of edema. The percentage inhibition was determined for the treated group with respect to the
control group. Indomethacin (50 mg/kg) and phenylbutazone (10 mg/kg) were included as
standard anti-inflammatory agents.
Writhing Reflex:
CF male mice were administered experimental drugs at 8 mg/kg, I.P., 20 min. prior to the
I.P. administration of 0.5 ml of 1.2% acetic acid according to the methods of Hendershot et al. [8]
and Vinegar et al. [9] After 5 min., the number of stretches, characterized by repeated
contractures of the abdominal musculature accompanied by hindlimb extension, was counted over
the next 10 min. Control mice demonstrated ~25 stretch reflexes/10 min. Indomethacin (50
mg/kg) was included as a standard analgesic agent.
Protection Against Septic shock:
CF male mice (~25g) were administered Salmonella lipopolysaccharide (LPS), 10 mg/kg
I.P., an amount that is lethal within 48-52 hours [10]. Drugs were administered, at 8 mg/kg, 2
hours before and 2 hours after injection of LPS and every 24 hours afterwards up to 48 hours.
Deaths were recorded daily for the length of the study. The percent death at 52 hr. was calculated
and compared to the control group, which afforded 16% survival at 52 hr. Indomethacin (50
mg/kg), phenylbutazone (10 mg/kg), pentoxifylline (50 mg/kg), and dexamethasone (1 mg/kg)
were included as standard antisepsis agents.
Statistical Analysis:
Data is displayed in tables 1-3 as the means + standard deviations or standard errors of the
mean. N is the number of samples or animals per group. The Student’s "t"-test was used to
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determine the probable level of significance (p) between test samples and control samples.
Results:
Chemistry:
The synthesis of derivatives of the boronated dipeptide N-[(trimethylamine-boryl)carbonyl]-
L-phenylalanine methyl ester was successfully accomplished in moderate yields using the coupling
agent triphenylphospine/carbon tetrachloride. The structures (Figure I) and purity of the
compounds were confirmed using elemental analysis, melting points, and both H-NMR and
infrared spectroscopy. All values were within acceptable limits (data available upon request).
N,N-dimethylglycyI-L-phenylalanine methyl ester was synthesized by using
dicyclohexylcarbodiimide (DCC) as the coupling agent with low yields, when the standard method
was unsuccessful.
In Vitro Cytotoxicity:
The compounds demonstrated in vitro cytotoxicity primarily in suspended tumor cell lines,
e.g., murine L12o lymphoid leukemia, human Tmolt3 T cell acute lymphoblastic leukemia, and
HeLa-S
3 suspended human uterine cervical carcinoma, with variable activity in human solid tumor
cell cultures (Table 1). Compounds 2, 3, and 6 demonstrated ED5o values against L121o growth < 3
ig/ml. Rat osteogenic sarcoma UMR-106 activity was noted for only compound 4 (ED5o < 4
ig/ml). Compound 1 produced the best activity in the Tmolt3 screen with an ED5o value of 1.31
ig/ml. Compounds 2-6 afforded ED5o values < 3 ig/ml in the HeLa-S
3 uterine carcinoma screen.
In contrast only compounds 1 and 2 were active against solid HeLa cervical carcinoma growth.
Against KB nasopharynx growth, compound 1 alone was active (ED5o = 1.99 ig/ml). Against
MB9812 bronchogenic lung growth, only compound 2 was active (EDso = 1.33 ig/ml). Compound
2 alone inhibited the growth of lung carcinoma A549 with an EDso of 2.97 ig/ml. None of the
compounds tested were active against the growth of colorectal adenocarcinoma SW-480, ileum
HCT-8, skin epidermoid A431, or HS-683 glioma.
In Vivo Hypolipidemic Activity:
Compounds 1-3, and 6 demonstrated significant activity as hypolipidemic agents on both
days 9 and 16, at 8 mg/kg/day, I.P., in CF male mice (Table II). The compounds were similarly
effective, reducing serum cholesterol levels in CF male mice 30-50%, on day 16. The most
effective hypocholesterolemic agent was compound 1, which caused a 48% reduction in serum
cholesterol levels on day 16. L-Phenylalanine methyl ester, 3, which reduced serum cholesterol
levels 39%, on day 16, had similar efficacy as the other boron containing agents. L-phenylalanine,
4, and boric acid, 5, did not significantly reduce serum cholesterol levels over 16 days.
Serum triglycerides were only significantly reduced by compounds 1, 3, and 6 on day 16
(Table II). The L-phenylalanine methyl ester, 3, was approximately equally active as the parent
compound 1. The other metabolites were not as active in reducing serum triglycerides at 8
mg/kg/day.
Winter’s Test:
The ability to significantly reduce the carageenan induced inflammation in CF male mice
footpads was demonstrated by compounds 1, 2 and 6 (Table III). Compounds 3-5 did not appear
to possess any activity. Compound 2 demonstrated the best inhibition of 40%. N,N-
dimethylglycyI-L-phenylalanine methyl ester, 6, was more active than the boronated parent
compound, 1 with 32% inhibition compared to 23% inhibition at 8 mg/kg x 2 for the parent 1.
Writhing Assay:
All of the compounds tested demonstrated the ability to significantly block local pain (Table
III). The most active compound from the derivatives of the boronated dipeptide N-
[(trimethylamine-boryl)-carbonyl]-L-phenylalanine methyl ester was 6, which reduced mouse
writhing reflex 52%, followed closely by 3, which provided a 50% reduction in writhing reflex. Both
were significantly more active than the parent compound, 1 with 17% reduction at 8 mg/kg.
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Table II- In V/vo Hypolipidemic Activity of Derivatives of the Boronated Dipeptide N-
[(Trimethylamine-boryl)carbonyl]-L-phenylalanine Methyl Ester in CF1 Male Mice at $
mglkglday, I.P. for 16 Days.
Percent of Control (mean + s.d.)
(N = 6)
Control
a
I
e
2
3
4
5
6
Lovastatin
Clofibrate=
Day 9
Serum Cholesterol
Day 16
100+5
b
75+/-6*
71+5"
69+5*
90+5
96+7
76+4*
100+5
c
52+3*
61+/-4"
61+/-5"
90:6
100+/-5
74+/-5*
85+/-4
87+/-6
p 0.001 = 1% carboxymethylcellulose
d 137 mg/dL serum triglyceride
125 mg/dL serum cholesterol
as reported by Sood et a [1]
Serum Triglycerides
Day 16
100+/-4
d
67+/-5*
88+/-5
63+/-5*
94+/-6
101+/-6
80+/-5*
86+/-7
75:L--6"
127 mg/dL serum cholesterol
8 mg/kg/day
g 150 mg/kg/day
Septic Shock:
All the compounds tested provided protection against LPS induced septic shock (Table III).
Compound 6, at 8 mg/kg/day, demonstrated the best protection against septic shock with 100% of
the mice surviving. Compound 6 was significantly more active than the parent compound, 1 which
demonstrated only 50 % protection at 8 mg/kg/day. After treatment with compounds 2-4 mouse
survival was 83% after 48 hours, while treatment with compound 5 resulted in 67% mouse survival
after 48 hours. All of the proposed metabolites of compound 1, compounds 3-6, were more
effective than the parent compound.
Table II1" In Vivo Anti-inflammatory, Analgesic, and Sepsis Prophylactic Activities of
Derivatives of the Boronated Dipeptide N-[(Trimethylamine-boryl)carbonyl]-L-
phenylalanine Methyl Ester in CF Male Mice at 8 mg/kg, I.P.
(N = 6)
Compound #
Control
1
c
2
3
4
5
6
Indomethacin
d
Phenylbutazone
e
Pentoxifylline
Dexamethasone
Winter’s Test
% Control
a
100+11
77+/-5*
60_+6*
90+/-4
83+5
8O+5
68+7*
22+/-4*
53+/-4*
Writhing
% Control
b
100
83
97
5O
77
95
48
43
Septic Shock
% Protection
17
50
83
83
83
67
100
33
0
66
83
p < 0.001
= 84 mg increase in paw weight
d 50 mg/kg
b 25 stretch reflexes per 10 min.
e 10 mg/kg
C as reported by $ood et al. [1]
50 mg/kg
g mg/kg
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Discussion:
This investigation of the proposed metabolites of N-[(trimethylamineboryl)-carbonyl]-L-
phenylalanine methyl ester 1, suggests that some of the metabolites may be responsible for the
observed pharmacological action. For example in the human lung A549 and MB9812 tumor
screens, the metabolite N-[(trimethylamineboryl)-carbonyl]-L-phenylalanine 2 afforded better
cytotoxic activity than the parent compound 1. In the L2o murine lymphoid leukemia screen 2, 3,
and 6 demonstrated better activity than the parent 1. In the HeLa-S3 screen the metabolites were
active but the parent was not. Whereas in the human Tmolt3 T cell leukemia screen only the
parent 1 was significantly active. In the HeLa and KB nasopharynx all of the metabolites were
inactive but the parent was active. Only L-phenylalanine 4 was marginally active in the rat UMR-
106 osteosarcoma screen. In some of the tumor lines (e.g., colon, ileum, skin, and glioma) none
of the compounds demonstrated cytotoxicity. It should be pointed out that these are in vitro
studies and it is unknown what the capability of each tumor line had with regard to metabolizing
compound 1. One would assume that hydrolytic enzymes (esterases and amidases) were present
at some concentration in all cell lines. There may also be species differences between murine,
rat, and human cell lines.
In the hypolipidemic in vivo screen, compounds 2, 3, and 6 demonstrated moderate activity
of 39%, 39%, and 26%, respectively. However, only compound 3 was as active as the parent 1
with a 37% reduction in serum triglyceride levels at 8 mg/kg/day. This suggested that the boron
atom was not necessary for hypolipidemic activity.
In the Winter’s test compounds 2 and 6 (methyl ester derivatives) demonstrated slightly
improved activity (32% and 40% respectively) over the parent 1 (23%) at 8 mg/kg. In the writhing
/ local pain assay compounds 3 and 6 demonstrated significantly improved activity (50-52%
reduction) over the parent 1 (17% reduction), in the LPS endotoxic shock assay the parent 1 only
resulted 50% protection from death. Compounds 2, 3, and 4 demonstrated improved protection
with 83% and compound 6 afforded 100% protection suggesting that all of the metabolites with
and without the methyl ester or boron were more effective than N-[(trimethylamineboryl)-carbonyl]-
L-phenylalanine methyl ester 1. Thus it may be concluded that the metabolites of 1 were
responsible for some of the observed pharmacological activity of compound 1. This response
varied in mice with the type of pharmacological activity tested.
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